There has been considerable activity with regard to Abbott Laboratories (ABT) according to the most recent bulletins. There is conjecture of a likely recovery in ABT's nutrition segment, and the integration of ABT's oncology test into OncoEMR has sparked curiosity about what it could mean for shareholders. Even though the stock is currently sitting 26% off its peak, analysts are backing a $132 mean price target. The investment in Whoop has placed digital health wearables front and center for shareholders. While sales of shares were reported by Banque Pictet & Cie SA and others such as J.Safra Sarasin Holding AG and SG Americas Securities LLC, new shares of ABT were purchased by firms including Shrier Wealth Management LCC, Mn Services Vermogensbeheer B.V., Net Worth Advisory Group and Franklin Resources Inc. Furthermore, the ERSTE Group has maintained their hold rating on ABT, with the investment case appearing brighter heading into Q1 earnings. ABT’s Libre has been linked to fewer heart hospitalizations in diabetes patients, and the recent announcement of the completion of the acquisition of Exact Sciences has the potential to shift ABT's narrative. Despite recent stumbles, Many analysts still see long-term upside to ABT.
Abbott Laboratories ABT News Analytics from Thu, 22 Jan 2026 08:00:00 GMT to Sat, 04 Apr 2026 13:05:33 GMT -
Rating 4
- Innovation 6
- Information 8
- Rumor -4
